Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 402

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 4
Chunk 402
---
 would be a “FIRST” in the nation.

Third, WEED established
WEED Australia Ltd. and its wholly owned Cannabis Institute of Australia (C.I.A.) in Australia in March of 2017, for the purpose of conducting
cannabis and hemp research and potentially developing products and educational services in and for Australians as stated above. C.I.A.
is a non-profit entity formed for the purpose of conducting cannabis and hemp research with universities and other non-profits to protect
all intellectual rights, properties and usage in our highly regulated industry. The C.I.A. has the potential to develop products in Australia
for domestic research and development of products, services and educational purposes to all seven States and territories, including Tasmania,
to be marketed globally.

21

Our first business opportunity
was, and continues to be, through our wholly-owned subsidiary, Sangre AT, LLC (“Sangre”), where we are focused on the development
and application of cannabis-derived compounds for the treatment of human disease and animal ailments. To that end Sangre, was working
on a planned five-year Cannabis Genomic Study to complete a genetic blueprint of the Cannabis plant genus, by creating a global genomic
classification of the entire plant. Sangre completed a 1-2 year Pilot Study in 2017 & 2018 at the University of Texas-Galveston thru
Industrial Metagenomics at a cost of nearly $1 million USD. Sangre completed the pilot study with 30 cultivars from strains collected
worldwide that included 30 strains (twenty-four female and six male). These results are highly proprietary and the basis of future studies
to come. We need to raise additional funds to continue the next steps in our Cannabis Genomic Study.

On May 14th, 2018, the 70th
Anniversary of the statehood of Israel, WEED formed its wholly owned subsidiary, WEED Israel Cannabis Ltd., with the goal of completing
and adding to the noted studies above. As such, WEED Israel worked with the Hebrew University in Jerusalem and with the top scientists
globally in the field of Cannabis & hemp. To that effect, WEED Israel looked to conduct clinical trials and product development that
would be the quality and acceptability of the FDA in the United States. Due to current laws and conditions in the USA, all research results
and product development for both Pharma & Non-Pharma products, cannot be introduced the United States marketplace. Since starting
in 2018, the